Trial Profile
A Placebo-controlled, Double-blind, Randomized, Dose-finding Phase II Study on OMT-28 in MaIntenance of Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (PROMISE-AF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs OMT 28 (Primary)
- Indications Atrial fibrillation
- Focus Proof of concept; Therapeutic Use
- Acronyms PROMISE-AF
- Sponsors OMEICOS Therapeutics
- 13 Sep 2021 Status changed from recruiting to completed.
- 16 May 2020 This trial has been completed in Bulgaria, Hungary and Portugal (Global End Date: 08 Apr 2020) according to European Clinical Trials Database record.
- 29 Apr 2019 According to an OMEICOS Therapeutics media release, first patient has been dosed, and completion of this trial is expected in H1 2020 H12020, and should enable OMEICOS to transition OMT-28 into Phase III clinical evaluation.